Douglas Kiehl is a Research Advisor at Eli Lilly and Company and leads the global Advanced Structural Characterization, Trace Analysis, Extractables/Leachables and Elemental Impurities team. Mr. Kiehl has over 37 years' experience with application of advanced mass spectrometry and related technologies in the characterization of diverse chemical entities, 25 years of which are in the Pharmaceutical Industry. He is a member of the USP Packaging and Distribution Expert Committee, the USP Expert Panel on Biocompatibility of Materials Used in Packaging Systems, Medical Devices and Implants, the USP Expert Panel on Elastomeric Closure for Injections, Board of Directors for the ELSIE (Extractables/Leachables Safety Information Exchange) Consortium, Chair for the SPIE Defense and Commercial Sensing Conference and member of the AAPS Impurities Steering Committee. His research interests include the development of advanced mapping and visualization techniques to enable the rapid and comprehensive characterization of highly complex mixtures of structurally and compositionally diverse chemical entities. He leads multidisciplinary govt/academia/industry collaborative efforts to advance the ultrarapid development, manufacture and deployment of pharmaceutical countermeasures for unanticipated/unmet medical needs and point-of-use patient therapies.